Korro Bio (KRRO) Gains from Sales and Divestitures (2024 - 2025)
Korro Bio's Gains from Sales and Divestitures was $18,000 in Q4 2025, compared with -$357,000 a year earlier.
Powered by 
Analysis
Korro Bio (KRRO) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends
For FY2025, Gains from Sales and Divestitures at Korro Bio came in at -$63,000.
- In earlier years, Gains from Sales and Divestitures was -$357,000 in FY2024, -$65,000 in FY2023 and -$16,000 in FY2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Korro Bio | 141.76 Mn | -254.88 Mn | - |
API Access
Korro Bio Gains from Sales and Divestitures API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KRRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gains-from-sales-and-divestitures", "ticker": "KRRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KRRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();